HSIC Q1 2026 Earnings Call Summary | Stock Taper
Logo
HSIC

HSIC — Henry Schein, Inc.

NASDAQ


Q1 2026 Earnings Call Summary

May 5, 2026

Summary of Henry Schein's Q1 2026 Earnings Call

1. Key Financial Results and Metrics

  • Global Sales: $3.4 billion, up 6.3% year-over-year.
  • GAAP Operating Margin: 5.41%, down 12 basis points from the previous year.
  • Non-GAAP Operating Margin: 7.53%, up 28 basis points, driven by gross margin expansion.
  • GAAP Net Income: $107 million ($0.92 per diluted share), compared to $110 million ($0.88 per diluted share) in Q1 2025.
  • Non-GAAP Net Income: $153 million ($1.32 per diluted share), up from $143 million ($1.15 per diluted share) in the prior year.
  • Adjusted EBITDA: $289 million, an 11.6% increase from $259 million in Q1 2025.
  • Operating Cash Flow: Negative $97 million due to seasonal decreases in accounts payable.

2. Strategic Updates and Business Highlights

  • BOLD+1 Strategy: Focus on enhancing operational execution and integrating technology to improve customer experience and efficiency.
  • Market Position: Strong competitive advantages in the dental market, with ongoing investments from Dental Service Organizations (DSOs) driving growth.
  • Product Development: Increased focus on AI solutions and technology integration, with successful launches at recent events.
  • Value Creation Initiatives: Targeting over $200 million in annual operating income improvement, with a $125 million run rate expected by the end of 2026.
  • E-commerce Expansion: Successful rollout of the global e-commerce platform, with over 80% of U.S. dental e-commerce sales now transacted online.

3. Forward Guidance and Outlook

  • 2026 Financial Guidance:
    • Total sales growth expected to be approximately 3% to 5%.
    • Non-GAAP diluted EPS projected between $5.23 and $5.37.
    • Adjusted EBITDA anticipated to grow in the mid-single digits.
    • Guidance assumes stable dental and medical end markets and mitigated impacts from rising oil prices.

4. Challenges and Points of Concern

  • Medical Business Softness: Decline in demand for point-of-care diagnostic products due to a light flu season, impacting overall medical sales.
  • Rising Costs: Concerns about increasing oil prices affecting freight and product costs, although management is implementing measures to mitigate these impacts.
  • Market Dynamics: Competitive pressures from lower-priced entrants in the digital equipment market, which may affect margins.

5. Notable Q&A Insights

  • Gross Margin Drivers: Improvements attributed to value creation initiatives and a dynamic pricing environment, with own brand products outpacing overall portfolio growth.
  • Specialty Products Growth: Expected to improve in subsequent quarters, with strong demand for value implants but flat performance in premium implants.
  • DSO Growth: DSOs are growing faster than the overall market, with Henry Schein positioned as a key partner due to its comprehensive support and technology offerings.
  • Customer Engagement: Management emphasizes the importance of maintaining strong relationships with customers, particularly when discussing price increases due to rising costs.

Overall, Henry Schein reported a strong start to 2026, with solid sales growth and strategic initiatives aimed at enhancing operational efficiency and customer service, despite facing challenges in the medical segment and rising costs.